Assembly Biosciences, Inc. (ASMB) Stock

Assembly Biosciences, Inc. (ASMB) is a Healthcare stock trading at $24.34 (as of 2026-06-18), with a market capitalization of $390.48M and a trailing P/E of 287.0. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Assembly Biosciences, Inc. is a clinical-stage biotechnology company developing therapeutic candidates to treat hepatitis B virus infection. Its pipeline includes Vebicorvir and other HBV-focused programs, with clinical and preclinical work in support of treatment of chronic HBV in the United States.

Valuation — source: SEC EDGAR (first-party)
Price$24.34
Market Cap$390.48M
P/E Ratio287.0
EV / EBITDA-24.9
Price / Book1.84
Price / Sales5.13
DCF Value (model)$-40.49
DCF Upside vs Price-266.4%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$72.30M
Net Margin-8.5%
Return on Equity-3.2%
Current Ratio6.65
Revenue Growth (YoY)-12.8%
EPS Growth (YoY)-53.8%
FCF Growth (YoY)-5.6%
Financial Health — source: SEC EDGAR
Altman Z-Score1.12 (distress)
Valuation vs Sector & Industry
Stock P/E287.0
Sector P/E (Healthcare)20.9
Industry P/E (Pharmaceutical Products)17.0
vs Sector1274.0%
vs Industry1586.9%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderGILEAD SCIENCES, INC. ($125.02M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOJason A. Okazaki
Employees73
CountryUS
IPO Date2010-12-17

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Corvus Pharmaceuticals, Inc. (CRVS)
  • Evommune, Inc. (EVMN)
  • Alto Neuroscience, Inc. (ANRO)
  • Design Therapeutics, Inc. (DSGN)
  • Kyverna Therapeutics, Inc. (KYTX)
  • LB Pharmaceuticals Inc Common Stock (LBRX)
  • Ironwood Pharmaceuticals, Inc. (IRWD)
  • Prothena Corporation plc (PRTA)
ASMB earnings history · ASMB institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.